Ventripoint Diagnostics (TSX. V: VPT) (OTC: VPTDF) interview with Dr. George Adams, CEO, discussing the company’s innovative AI-driven medical imaging technology addressing the cardio and cancer markets. The company has recently entered commercialization stage, and Dr. Admas provides an updates on the sales pipeline, and future growth potential.
Investor Presentation
Ventripoint Presentation
Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for subscribing. Something went wrong. Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of […]
Hoth Therapeutics, Inc. (NASDAQ: HOTH) will be a featured presenter at Wall Street Reporter’s Next Super Stock Live! online investor conference on September 25, 2019. Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank […]
FORT LAUDERDALE, Fla.—-MEDNAX, Inc. (NYSE:MD), today announced the acquisition of Women’s Radiology Associates, LLP, a private radiology physician group based in Houston. The practice will integrate with Synergy Radiology Associates, a MEDNAX-affiliated physician practice, also […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
